What do we do with chronic lymphocytic leukemia with 17p deletion?
Curr Hematol Malig Rep
; 8(1): 81-90, 2013 Mar.
Article
em En
| MEDLINE
| ID: mdl-23188619
ABSTRACT
Chronic lymphocytic leukemia (CLL) with 17p deletion or mutations of the TP53 gene has a very poor outcome. Optimal treatment of these patients remains a major clinical challenge, and disagreement on the optimal treatment approach exists. Conventional chemo-immunotherapy with rituximab in combination with purine analogues yields lower response-rates and less satisfactory results than for CLL patients with intact p53. Allogeneic stem cell transplantation may allow long-term remissions in this challenging group of patients. In this review, we will discuss current treatment options as well as experimental approaches in clinical trials for CLL patients with deleted or mutated TP53. Particular emphasis will be placed on novel agents with the potential to change clinical practice and future perspectives for the management of these "highest risk" patients.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cromossomos Humanos Par 17
/
Leucemia Linfocítica Crônica de Células B
/
Genes p53
/
Proteína Supressora de Tumor p53
/
Deleção de Sequência
Limite:
Humans
Idioma:
En
Revista:
Curr Hematol Malig Rep
Ano de publicação:
2013
Tipo de documento:
Article